ABCG2 p.Arg482Ser

Predicted by SNAP2: A: D (91%), C: D (85%), D: D (95%), E: D (95%), F: D (91%), G: D (95%), H: D (95%), I: D (85%), K: D (85%), L: D (91%), M: D (85%), N: D (95%), P: D (95%), Q: D (95%), S: D (91%), T: D (91%), V: D (91%), W: D (95%), Y: D (95%),
Predicted by PROVEAN: A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, S: D, T: D, V: D, W: D, Y: D,

[switch to compact view]
Comments [show]
Publications
[hide] Allen JD, Jackson SC, Schinkel AH
A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.
Cancer Res. 2002 Apr 15;62(8):2294-9., 2002-04-15 [PMID:11956086] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Cancer Res. 2002 Sep 1;62(17):5035-40., 2002-09-01 [PMID:12208758] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ozvegy C, Varadi A, Sarkadi B
Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
J Biol Chem. 2002 Dec 13;277(50):47980-90. Epub 2002 Oct 8., 2002-12-13 [PMID:12374800] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y
Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Int J Cancer. 2003 Dec 10;107(5):757-63., 2003-12-10 [PMID:14566825] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.
Br J Cancer. 2003 Nov 17;89(10):1971-8., 2003-11-17 [PMID:14612912] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A
ABCG2 -- a transporter for all seasons.
FEBS Lett. 2004 Jun 1;567(1):116-20., 2004-06-01 [PMID:15165903] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A
Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Biochim Biophys Acta. 2005 Feb 1;1668(1):53-63., 2005-02-01 [PMID:15670731] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J
Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
Cancer Sci. 2005 Aug;96(8):457-65., [PMID:16108826] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Krishnamurthy P, Schuetz JD
The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival.
Biometals. 2005 Aug;18(4):349-58., [PMID:16158227] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG
ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Cancer Res. 2005 Sep 15;65(18):8414-22., 2005-09-15 [PMID:16166320] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Cervenak J, Andrikovics H, Ozvegy-Laczka C, Tordai A, Nemet K, Varadi A, Sarkadi B
The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.
Cancer Lett. 2006 Mar 8;234(1):62-72. Epub 2005 Dec 7., 2006-03-08 [PMID:16337740] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Sarkadi B, Homolya L, Szakacs G, Varadi A
Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.
Physiol Rev. 2006 Oct;86(4):1179-236., [PMID:17015488] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y
Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene.
Cancer Sci. 2010 Jun;101(6):1493-500. Epub 2010 Feb 22., [PMID:20345483] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Telbisz A, Hegedus C, Varadi A, Sarkadi B, Ozvegy-Laczka C
Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites.
Drug Metab Dispos. 2014 Apr;42(4):575-85. doi: 10.1124/dmd.113.055731. Epub 2014 Jan 2., [PMID:24384916] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]